1.19
-0.03(-2.46%)
Currency In USD
| Previous Close | 1.22 |
| Open | 1.21 |
| Day High | 1.21 |
| Day Low | 1.18 |
| 52-Week High | 3.09 |
| 52-Week Low | 0.26 |
| Volume | 168,947 |
| Average Volume | 962,655 |
| Market Cap | 219.49M |
| PE | -5.41 |
| EPS | -0.22 |
| Moving Average 50 Days | 1.2 |
| Moving Average 200 Days | 1.22 |
| Change | -0.03 |
If you invested $1000 in Tevogen Bio Holdings Inc. (TVGN) since IPO date, it would be worth $119.72 as of July 12, 2025 at a share price of $1.19. Whereas If you bought $1000 worth of Tevogen Bio Holdings Inc. (TVGN) shares 2 years ago, it would be worth $109.98 as of July 12, 2025 at a share price of $1.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
GlobeNewswire Inc.
Jul 10, 2025 7:13 PM GMT
CEO's personal contribution fully funds build-out and first-year operationsDoubled HQ footprint centralizes cross-functional teams, including research, regulatory affairs, and the expanding Tevogen.AI initiative WARREN, N.J., July 10, 2025 (GLOBE
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
GlobeNewswire Inc.
Jun 30, 2025 6:28 PM GMT
Contribution highlights leadership’s understanding of the importance AI will play in drug discovery WARREN, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that founder and C
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
GlobeNewswire Inc.
Jun 18, 2025 12:30 PM GMT
WARREN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today provided an update on its ongoing development of a cytotoxic T lymphocyte (CTL) therapy targeting Epstein-Barr virus (EBV)-assoc